Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
8
Neutral
2
Bullish
4
Bearish
8
Neutral
2
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities.
In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer.
Venus Remedies has been expanding its consumer healthcare product line, notably launching R3SET, a pain management solution, in 2021-22.
The company has focused on process automation and business intelligence, adopting systems such as retail billing automation and implementing a BI tool like Tableau for decision-making.
Recent advancements in their R&D efforts include the launch of ELORES, an antibiotic that tackles superbugs, significantly strengthening its product portfolio.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,715 Cr
Low Risk
16.7
33.9
7.0
2.6
1,282.85
410.10
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
209.50 | 1,935 Cr | -20.34 | 2.06 | 0.10 | -10.13 | 0.77 | -3.81 | ||
796.50 | 1,772 Cr | 58.14 | 5.46 | 0.00 | 9.40 | 12.54 | 6.34 | ||
2805.00 | 1,723 Cr | 35.85 | 5.23 | 0.00 | 14.62 | 15.37 | 8.81 | ||
826.00 | 1,717 Cr | 25.84 | 2.96 | 0.77 | 11.44 | 14.90 | 7.32 | ||
1282.85 | 1,715 Cr | 16.68 | 2.58 | 0.00 | 15.49 | 19.85 | 12.04 | ||
1996.50 | 1,702 Cr | 30.59 | 4.73 | 0.55 | 15.45 | 14.34 | 8.48 | ||
559.55 | 1,618 Cr | 27.93 | 4.37 | 0.00 | 17.42 | 23.31 | 11.38 | ||
| Median: 7 Co. | — | 826.00 | 1,717 Cr | 27.93 | 4.37 | 0.00 | 14.62 | 14.90 | 8.48 |
Audited Results
Venus Remedies published audited consolidated and standalone results for year ended 31-Mar-2026; consolidated income from operations rose to 769.60 (vs 652.89) and standalone PAT was 99.31 (vs 52.55); Board approved on 26-May-2026.
Board Meeting Outcome
Venus Remedies' Board (26 May 2026) approved audited standalone and consolidated results for quarter/year ended 31 Mar 2026, recommended final dividend of Rs10/share (100%) subject to shareholder approval; AGM on 20 Aug 2026 (record date 07 Aug); board appointments, cost/internal auditor appointments and adoption of new MoA/AoA proposed.
Board Meeting Outcome
Venus Remedies' Board (26 May 2026) approved audited standalone & consolidated results for Q4/FY ended 31 Mar 2026, recommended final dividend of Rs10/- (100%) per share (subject to shareholder approval; record date 07 Aug 2026), scheduled 37th AGM on 20 Aug 2026, appointed Dr. Gurminder Singh Bedi (Additional Independent Director) and approved cost/internal auditor appointments; new MOA/AOA to be placed for shareholder approval.
Board meeting outcome
Venus Remedies approved audited standalone & consolidated results for quarter/year ended Mar 31, 2026 (unmodified audit); proposed final dividend Rs10/share subject to AGM approval (record date Aug 7, 2026); AGM on Aug 20, 2026; director and auditor appointments; adoption of MOA/AOA subject to shareholder approval.
Board Meeting Outcome
26‑May‑2026 board meeting: approved audited standalone & consolidated FY2025‑26 results with unmodified opinion; recommended final dividend of Rs10/share (subject to AGM approval, record date 07‑Aug‑2026); adoption of revised MOA/AOA, director and auditor appointments, and trading window closure.
Board Meeting Outcome
Board meeting (26‑May‑2026) approved audited standalone & consolidated results for quarter/year ended 31‑Mar‑2026, recommended final dividend of Rs10/share (subject to shareholder approval), fixed AGM on 20‑Aug‑2026, appointed/re‑appointed directors and cost/internal auditors and proposed amendments to MoA/AoA.
Venus Remedies Ltd (VENUSREM) is currently trading at 1,282.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities. In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer. Venus Remedies has been expanding its consumer healthcare product line, notably launching R3SET, a pain management solution, in 2021-22. The company has focused on process automation and business intelligence, adopting systems such as retail billing automation and implementing a BI tool like Tableau for decision-making. Recent advancements in their R&D efforts include the launch of ELORES, an antibiotic that tackles superbugs, significantly strengthening its product portfolio.
Over the past 52 weeks, Venus Remedies Ltd has traded between a low of ₹410.10 and a high of ₹1,282.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Venus Remedies Ltd has a market capitalization of approximately 1,714.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Venus Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.68 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,714.78 Cr, Venus Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Venus Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Venus Remedies Ltd is 16.68. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Venus Remedies received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a speciality oncology therapy.
